A POLY (ADP-RIBOSE) POLYMERASE-1 (PARP-1) INHIBITOR AND USES THEREFOR
申请人:Washington University
公开号:EP3424909A1
公开(公告)日:2019-01-09
Disclosed are Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors. Further disclosed are methods of synthesis. Of the compounds synthesized, 2-[p-(2-Fluoroethoxy)phenyl]-1.3.10-triazatricyclo[6.4.1.04,13]trideca-2,4(13),5,7-tetraen-9-one (12) had the highest inhibition potency for PARP-1 (IC50 = 6.3 nM).
TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES
申请人:AGOURON PHARMACEUTICALS, INC.
公开号:EP1208104B1
公开(公告)日:2005-01-19
US6548494B1
申请人:——
公开号:US6548494B1
公开(公告)日:2003-04-15
US9993570B2
申请人:——
公开号:US9993570B2
公开(公告)日:2018-06-12
Tricyclic inhibitors of poly(ADP-ribose) polymerases
申请人:Agouron Pharmaceuticals, Inc.
公开号:US06548494B1
公开(公告)日:2003-04-15
Compounds of the formula shown below are poly(ADP-ribosyl)transferase inhibitors:
Such compounds are useful as therapeutics in treating cancers and in ameliorating the effects of stroke, head trauma, and neurodegenerative disease.